Sjoerd H. van der Burg
0000-0002-6556-0354
Publication & Citation Trends
Publications
0 total
EP330/#475 Immune-based biomarker accurately predicts response to imiquimod immunotherapy in cervical high-grade squamous intraepithelial lesions OA
Cited by 0
Semantic Scholar
343 Identification of tumor-reactive T cells targeting melanoma Dark Antigens™ validates this novel class of targets for development of immunotherapies OA
Cited by 1
Semantic Scholar
1181 Therapeutic vaccines consisting of cancer germline antigen-based synthetic long peptides are immunogenic in human hepatocellular carcinoma patients OA
Cited by 0
Semantic Scholar
356 Personalized immunotherapy by adoptive T cell transfer during chemotherapy with or without interferon-alpha in patients with recurrent platinum-sensitive epithelial ovarian cancer OA
Cited by 0
Semantic Scholar
35 Chemokine-driven spatial organization of immune cell microaggregates marks oropharyngeal squamous cell carcinomas containing tumor-specific T cells OA
Cited by 0
Semantic Scholar
Abstract 1582: A pre-existing inflammatory immune microenvironment predicts the clinical and immunological response of vulvar high-grade squamous intraepithelial lesions to therapeutic HPV16 peptide vaccination
Cited by 0
Semantic Scholar
580P AT1412, a patient-derived CD9 antibody promotes tumour immune infiltration and induces tumour rejection OA
Cited by 1
Semantic Scholar
Abstract 531: AT1412, a patient-derived antibody in development for the treatment of CD9-positive precursor B-acute lymphoblastic leukemia
Cited by 0
Semantic Scholar
Research Topics
Immunotherapy and Immune Responses
(416)
Cancer Immunotherapy and Biomarkers
(247)
CAR-T cell therapy research
(195)
Immune Cell Function and Interaction
(157)
Cervical Cancer and HPV Research
(142)
Affiliations
Leiden University
American Society of Clinical Oncology
Johns Hopkins University
Duke University
University of California, San Francisco